Complete financial analysis of Bio-View Ltd (BIOV.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-View Ltd, a leading company in the Medical – Devices industry within the Healthcare sector.
- Earth Search Sciences, Inc. (ESSE) Income Statement Analysis – Financial Results
- Shenzhen Breo Technology Co., Ltd. (688793.SS) Income Statement Analysis – Financial Results
- Fifth Third Bancorp (0IM1.L) Income Statement Analysis – Financial Results
- Kimberly-Clark de México, S. A. B. de C. V. (KIMBERA.MX) Income Statement Analysis – Financial Results
- Genelux Corporation (GNLX) Income Statement Analysis – Financial Results
Bio-View Ltd (BIOV.TA)
About Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. Its products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation with advanced review and analysis tools; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 2000 and is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.77M | 29.15M | 30.51M | 25.96M | 35.79M | 25.28M | 27.76M | 33.29M | 34.53M | 30.24M | 23.03M | 26.05M | 26.17M | 25.32M |
| Cost of Revenue | 13.39M | 12.48M | 12.93M | 10.18M | 15.52M | 10.52M | 11.18M | 12.11M | 13.05M | 10.70M | 8.24M | 8.89M | 8.67M | 9.83M |
| Gross Profit | 21.38M | 16.67M | 17.59M | 15.78M | 20.27M | 14.76M | 16.58M | 21.18M | 21.48M | 19.54M | 14.79M | 17.16M | 17.50M | 15.49M |
| Gross Profit Ratio | 61.48% | 57.20% | 57.63% | 60.80% | 56.63% | 58.39% | 59.71% | 63.61% | 62.20% | 64.61% | 64.23% | 65.87% | 66.86% | 61.16% |
| Research & Development | 8.41M | 4.85M | 5.33M | 5.35M | 5.71M | 265.00K | 231.00K | 5.68M | 5.56M | 5.24M | 5.69M | 5.40M | 3.88M | 3.53M |
| General & Administrative | 7.49M | 3.23M | 1.85M | 1.92M | 2.09M | 7.64M | 7.15M | 4.58M | 4.85M | 5.22M | 4.23M | 4.10M | 3.79M | 3.40M |
| Selling & Marketing | 5.33M | 993.00K | 601.00K | 355.00K | 917.00K | 980.00K | 1.12M | 6.12M | 6.99M | 7.01M | 5.82M | 5.79M | 5.72M | 4.89M |
| SG&A | 12.83M | 4.23M | 2.45M | 2.28M | 3.01M | 8.62M | 8.27M | 10.71M | 11.84M | 12.23M | 10.06M | 9.89M | 9.52M | 8.29M |
| Other Expenses | -629.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.61M | 16.57M | 14.04M | 13.61M | 15.91M | 17.39M | 16.86M | 16.41M | 17.61M | 18.06M | 15.53M | 15.20M | 13.89M | 11.24M |
| Cost & Expenses | 34.00M | 29.04M | 26.96M | 23.79M | 31.43M | 27.91M | 28.04M | 28.53M | 30.66M | 28.77M | 23.77M | 24.09M | 22.56M | 21.08M |
| Interest Income | 443.00K | 28.00K | 21.00K | 44.00K | 86.00K | 92.00K | 87.00K | 54.00K | 24.00K | 24.00K | 88.00K | 208.00K | 171.00K | 19.00K |
| Interest Expense | 311.00K | 236.00K | 232.00K | 46.00K | 63.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 238.00K | 333.00K | 360.00K |
| Depreciation & Amortization | 1.82M | 1.50M | 1.48M | 1.23M | 1.40M | 541.00K | 289.00K | 200.00K | 389.00K | 498.00K | 537.00K | 490.00K | 487.00K | 395.00K |
| EBITDA | 2.93M | 2.61M | 4.03M | 2.43M | 4.94M | -2.05M | -143.00K | 4.96M | 4.26M | 1.98M | -204.00K | 2.45M | 4.09M | 4.24M |
| EBITDA Ratio | 8.42% | 8.94% | 15.52% | 9.71% | 13.81% | -8.01% | -0.52% | 14.85% | 11.95% | 6.88% | -0.89% | 9.46% | 15.64% | 16.76% |
| Operating Income | 766.00K | 1.15M | 2.95M | 1.20M | 3.40M | -1.77M | -1.41M | 4.74M | 3.85M | 2.51M | -1.09M | 1.72M | 3.93M | 3.85M |
| Operating Income Ratio | 2.20% | 3.95% | 9.67% | 4.63% | 9.49% | -6.98% | -5.09% | 14.23% | 11.13% | 8.30% | -4.75% | 6.60% | 15.01% | 15.20% |
| Total Other Income/Expenses | 31.00K | -276.00K | -267.00K | -60.00K | -27.00K | -61.00K | 117.00K | -76.00K | -22.00K | -271.00K | -94.00K | -45.00K | -162.00K | -341.00K |
| Income Before Tax | 797.00K | 875.00K | 2.68M | 1.14M | 3.37M | -1.83M | -1.30M | 4.66M | 3.82M | 2.24M | -1.19M | 1.67M | 3.77M | 3.51M |
| Income Before Tax Ratio | 2.29% | 3.00% | 8.79% | 4.40% | 9.41% | -7.22% | -4.67% | 14.00% | 11.07% | 7.41% | -5.16% | 6.42% | 14.39% | 13.85% |
| Income Tax Expense | 414.00K | 288.00K | 499.00K | 257.00K | 843.00K | 28.00K | -44.00K | 223.00K | -243.00K | 132.00K | -111.00K | 231.00K | -2.81M | -1.73M |
| Net Income | 383.00K | 587.00K | 2.18M | 884.00K | 2.53M | -1.85M | -1.25M | 4.44M | 4.07M | 2.11M | -1.08M | 1.44M | 6.58M | 5.24M |
| Net Income Ratio | 1.10% | 2.01% | 7.16% | 3.41% | 7.06% | -7.33% | -4.51% | 13.33% | 11.77% | 6.97% | -4.67% | 5.54% | 25.13% | 20.68% |
| EPS | 0.00 | 0.05 | 0.16 | 0.06 | 0.18 | -0.13 | -0.09 | 0.32 | 0.30 | 0.16 | -0.08 | 0.11 | 0.49 | 0.41 |
| EPS Diluted | 0.00 | 0.05 | 0.16 | 0.06 | 0.18 | -0.13 | -0.09 | 0.32 | 0.29 | 0.15 | -0.08 | 0.11 | 0.48 | 0.39 |
| Weighted Avg Shares Out | 135.43M | 13.91M | 13.98M | 14.06M | 14.19M | 14.13M | 13.96M | 13.89M | 13.71M | 13.51M | 13.42M | 13.36M | 13.30M | 12.71M |
| Weighted Avg Shares Out (Dil) | 140.12M | 13.91M | 13.98M | 14.06M | 14.19M | 14.13M | 13.96M | 13.89M | 13.83M | 13.65M | 13.42M | 13.47M | 13.59M | 13.28M |
Source: https://incomestatements.info
Category: Stock Reports